* ZAI LAB LTD - COLLABORATION WILL FACILITATE ENROLLMENT OF GLOBAL PHASE 3 TRIAL OF ETX2514 IN COMBINATION WITH SULBACTAM * ZAI LAB LTD - ZAI LAB WILL MANAGE PORTION OF PHASE 3 TRIAL CONDUCTED IN ...
WALTHAM, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
Entasis Therapeutics Holdings Inc. has described mannan-binding lectin serine protease 2 (MASP2) and/or mannan-binding lectin serine protease 3 (MASP3) inhibitors reported to be useful for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback